Table 3

Univariate and multivariable analysis for relative survival stratified by age for patients naive to systemic treatment

Characteristic

Patients < 65 years

Patients > 65 years


Univariate analysis

Multivariable analysis

Univariate analysis

Multivariable analysis


N

RER

95% CI

P

RER

95% CI

P

N

RER

95% CI

P

RER

95% CI

P


Age

.06

.10


< 40

33

1

1

0


40-50

98

1.03

0.51-2.08

0.69

0.21-2.24

0


50-60

101

1.52

0.76-3.03

1.38

0.46-5.18

0


> 60

44

2.16

0.99-4.66

1.93

0.56-6.57

154


Grade

.03

.95

.34


I

31

1

1

24

1


II

131

2.23

0.80-6.28

1.24

0.31-5.03

74

3.10

0.43-22.4


III

75

3.48

1.22-9.94

1.27

0.30-5.45

44

4.23

0.56-31.8


Histological type

.80

.37


Ductal

223

1

124

1


Other

15

1.12

0.46-2.71

18

1.49

0.62-3.61


Tumor stage

< .001

.33

.01

.09


pT1

137

1

1

59

1

1.00


pT2

109

2.67

1.41-3.64

1.42

0.73-2.76

71

5.47

0.83-35.9

4.26

0.71-25.4


pT3/4

22

4.26

2.29-7.94

1.79

0.81-3.95

18

13.2

1.90-92.1

7.90

1.18-52.9


Nodal stage

< .001

< .001

.02

.43


Negative

204

1

1

109

1

1.00


Positive

69

5.03

3.32-7.62

5.82

3.16-10.7

36

2.76

1.20-6.35

1.48

0.56-3.92


ER status

.11

.91


Negative

87

1

40

1


Positive

126

0.70

0.45-1.09

95

0.95

0.42-2.17


PgR status

.25

.58


Negative

84

1

55

1


Positive

123

0.77

0.49-1.21

81

0.80

0.36-1.77


HER2 status

.19

.89


Negative

143

1

105

1


Positive

19

1.57

0.80-3.09

4

0.85

0.09-8.40


ALDH1 status

.008

.02

.35


Negative

77

1

1

63

1


Positive

116

2.12

1.22-3.68

2.36

1.17-4.73

61

0.68

0.30-1.53


Abbreviations: N number of patients; RER relative excess risk; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; ALDH1 aldehyde dehydrogenase 1

Mieog et al. BMC Cancer 2012 12:42   doi:10.1186/1471-2407-12-42

Open Data